Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company is focusing on the development of chimeric antigen receptor (CAR)-based immunotherapies using autologous T-cells. It is developing CD38 Directed CAR-T, a cellular therapy used for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; CD123 Directed CAR-T for the treatment of acute myelogenous leukemia; and human antibodies, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT, and CD137. The company is also developing intracellular targeting antibodies comprising STAT3, Mutant KRAS, MYC, p53, and TAU to modulate the evolution of cancer, inflammation, autoimmune diseases, diabetes, central nervous system diseases, cardiovascular diseases, and viral infections; and oncolytic viruses that infect and selectively multiply in and destroy tumor cells without damaging healthy tissue. In addition, it offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company has a licensing agreement with Mabtech Limited to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from based on Erbitux, Remicade, Xolair, and Simulect. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SRNE
CUSIPN/A
Phone858-203-4100
Debt
Debt-to-Equity Ratio0.02
Current Ratio0.71
Quick Ratio0.71
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$151.85 million
Price / Sales5.04
Cash Flow$0.2045 per share
Price / Cash32.37
Book Value$2.50 per share
Price / Book2.65
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$9.13 million
Net Margins23.25%
Return on Equity21.31%
Return on Assets8.09%
Miscellaneous
Employees162
Outstanding Shares115,500,000
Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions
What is Sorrento Therapeutics' stock symbol?
Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."
How were Sorrento Therapeutics' earnings last quarter?
Sorrento Therapeutics Inc (NASDAQ:SRNE) released its earnings results on Monday, November, 16th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter. The biopharmaceutical company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.28 million. Sorrento Therapeutics had a net margin of 23.25% and a return on equity of 21.31%. View Sorrento Therapeutics' Earnings History.
What price target have analysts set for SRNE?
4 Wall Street analysts have issued twelve-month price objectives for Sorrento Therapeutics' stock. Their forecasts range from $7.00 to $40.00. On average, they expect Sorrento Therapeutics' share price to reach $15.75 in the next twelve months. View Analyst Ratings for Sorrento Therapeutics.
Who are some of Sorrento Therapeutics' key competitors?
Some companies that are related to Sorrento Therapeutics include BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Eloxx Pharmaceuticals (ELOX), Viralytics (VRACY), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI), Luna Innovations (LUNA), Senomyx (SNMX), Dyadic International, Inc common stock (DYAI), Vitality Biopharma (VBIO) and BIOQUAL (BIOQ).
Who are Sorrento Therapeutics' key executives?
Sorrento Therapeutics' management team includes the folowing people:
- Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 54)
- Mr. George K. Ng, Exec. VP, Chief Admin. Officer & Chief Legal Officer (Age 44)
- Dr. Jerome Bernard Zeldis, Chief Medical Officer and Pres of Clinical Research, Medical Affairs & Regulatory (Age 68)
- Mr. Jiong Shao CFA, Exec. VP & CFO (Age 50)
- Dr. Alexis Nahama, VP of Corp. Devel.
Has Sorrento Therapeutics been receiving favorable news coverage?
Media stories about SRNE stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sorrento Therapeutics earned a media sentiment score of 0.09 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 47.02 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Sorrento Therapeutics' major shareholders?
Sorrento Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.40%), Millennium Management LLC (1.55%), Wells Fargo & Company MN (0.55%), UBS Group AG (0.48%), Alambic Investment Management L.P. (0.46%) and Candriam Luxembourg S.C.A. (0.34%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd, George K Ng, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde, Pacific Medtech (Bvi) Ltd Asia, Patrick Soon-Shiong and Yue Alexander Wu. View Institutional Ownership Trends for Sorrento Therapeutics.
Which institutional investors are buying Sorrento Therapeutics stock?
SRNE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, UBS Group AG, Alambic Investment Management L.P., Candriam Luxembourg S.C.A., A.R.T. Advisors LLC, GSA Capital Partners LLP and Citigroup Inc.. Company insiders that have bought Sorrento Therapeutics stock in the last two years include Abg Management Ltd, George K Ng, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde and Yue Alexander Wu. View Insider Buying and Selling for Sorrento Therapeutics.
How do I buy shares of Sorrento Therapeutics?
Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sorrento Therapeutics' stock price today?
One share of SRNE stock can currently be purchased for approximately $6.62.
How big of a company is Sorrento Therapeutics?
Sorrento Therapeutics has a market capitalization of $843.12 million and generates $151.85 million in revenue each year. Sorrento Therapeutics employs 162 workers across the globe.
How can I contact Sorrento Therapeutics?
Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]
MarketBeat Community Rating for Sorrento Therapeutics (SRNE)
MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe SRNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
